Announcements
- Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process
- Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023
- Mithra secures court protection measures to advance monetization process
- Mithra reports full year 2023 financial results
- Mithra announces changes to its executive management
- Mithra initiates monetization process, receives bridge loan from existing lenders
- DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase
- Mithra sells shares in Mayne Pharma
- Mithra updates on cash position
- Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
More ▼
Key statistics
As of last trade Mithra Pharmaceuticals SA (1TM:BER) traded at 0.00, -100.00% above its 52-week low of 0.204, set on Mar 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 0.1864 |
Offer | 0.2485 |
Previous close | 0.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 66.91m |
Free float | 54.24m |
P/E (TTM) | -- |
Market cap | 14.45m EUR |
EPS (TTM) | -2.51 EUR |
Data delayed at least 15 minutes, as of Apr 29 2024 08:24 BST.
More ▼